Probi (PROB.ST) Stock Price
Probi Price
Revenue has compounded at 12.8% per year over the past 19 years to 627.69 M SEK. Earnings per share have grown at 3.7% per year over the last 19 years. Probi's net margin stands at 2.7%, down from 13.7% several years earlier. Probi currently offers a dividend yield of about 0.37%. The payout ratio is around 88% of earnings. The dividend has grown at 8.1% per year over the past 13 years.
Probi stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Probi over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Probi stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Probi's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Probi Price |
|---|
Probi Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Probi Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| DIVIDENDDIV.SEK |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.00 | 100.00 | 103.00 | 137.00 | 215.00 | 443.00 | 612.00 | 604.00 | 626.00 | 717.00 | 658.00 | 618.00 | 627.00 | – | 666.00 | 703.00 |
| 17.50 | 6.38 | 3.00 | 33.01 | 56.93 | 106.05 | 38.15 | -1.31 | 3.64 | 14.54 | -8.23 | -6.08 | 1.46 | – | – | 5.56 |
| 81.91 | 81.00 | 74.76 | 70.07 | 70.70 | 60.95 | 45.26 | 46.03 | 46.49 | 43.10 | 43.77 | 41.26 | 35.09 | – | 35.09 | 35.09 |
| 77.00 | 81.00 | 77.00 | 96.00 | 152.00 | 270.00 | 277.00 | 278.00 | 291.00 | 309.00 | 288.00 | 255.00 | 220.00 | 220.00 | 233.68 | 246.67 |
| 17.00 | 17.00 | 18.00 | 27.00 | 63.00 | 130.00 | 98.00 | 104.00 | 111.00 | 123.00 | 109.00 | 51.00 | 11.00 | 11.00 | 84.00 | 89.00 |
| 18.09 | 17.00 | 17.48 | 19.71 | 29.30 | 29.35 | 16.01 | 17.22 | 17.73 | 17.15 | 16.57 | 8.25 | 1.75 | – | 12.61 | 12.66 |
| 14.00 | 13.00 | 15.00 | 21.00 | 49.00 | 108.00 | 69.00 | 76.00 | 85.00 | 92.00 | 83.00 | 40.00 | 16.00 | – | 57.00 | 69.00 |
| 7.69 | -7.14 | 15.38 | 40.00 | 133.33 | 120.41 | -36.11 | 10.14 | 11.84 | 8.24 | -9.78 | -51.81 | -60.00 | – | – | 21.05 |
| – | – | – | – | – | – | – | – | – | – | – | – | 1.30 | 1.30 | 1.30 | 1.30 |
| 9.66 | 9.66 | 9.66 | 9.66 | 9.66 | 9.66 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Probi generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Probi retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Probi's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Probi has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Probi's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Probi stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Probi Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Probi business model & stock analysis
Probi SWOT Analysis
Strengths
Probi AB is well-known for producing high-quality probiotic products that promote gut health. The company has a strong global presence, with a wide distribution network and a solid market share. Probi AB has a robust research and development department, constantly innovating and improving their product offerings. The company has a strong financial position, allowing them to invest in production facilities and marketing initiatives.
Weaknesses
Probi AB is highly dependent on the success of their probiotic products, leaving little diversification in their portfolio. The company faces intense competition from other manufacturers in the probiotics market. Probi AB may experience supply chain challenges, especially with the sourcing of raw materials for their products. The company's manufacturing processes may be vulnerable to quality control issues, impacting product consistency.
Opportunities
The growing consumer awareness of the importance of gut health provides a significant opportunity for Probi AB to expand its customer base. There is an increasing demand for natural and functional ingredients, which aligns with Probi AB's product offerings. Probi AB can explore new markets and distribution channels, such as online sales and partnerships with retailers. The company can expand its product portfolio to include innovative probiotic solutions for different health conditions.
Threats
Probi AB faces regulatory challenges in certain markets, leading to potential restrictions or increased compliance costs. The company may encounter intellectual property disputes or face the risk of imitation products. Fluctuations in currency exchange rates can impact Probi AB's profitability, especially in international markets. The probiotics market is continuously evolving, and technological advancements or new entrants could disrupt the industry.
Probi Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Probi historical P/E ratio, EBIT multiple, and P/S ratio
Probi annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Probi's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Probi's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Probi's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Probi shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Probi Dividend History
13 years of dividend payments
Probi dividend history and estimates
Max
Details
Probi dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Probi Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 10/22/2024 | -SEK | 0.31SEK | 162.40 MSEK | - | 2024 Q3 |
| 7/15/2024 | 0.23SEK | 0.23SEK | 178.90 MSEK | - | 2024 Q2 |
| 4/23/2024 | -SEK | 0.71SEK | 174.10 MSEK | - | 2024 Q1 |
| 1/26/2024 | -SEK | -0.23SEK | 171.82 MSEK | - | 2023 Q4 |
| 10/24/2023 | -SEK | 0.56SEK | 144.00 MSEK | - | 2023 Q3 |
| 7/18/2023 | -SEK | -0.55SEK | 155.00 MSEK | - | 2023 Q2 |
| 4/26/2023 | -SEK | 1.69SEK | 153.00 MSEK | - | 2023 Q1 |
| 1/27/2023 | 1.89SEK | -0.50SEK | 171.00 MSEK | - | 2022 Q4 |
| 10/21/2022 | 2.13SEK | 1.09SEK | 173.00 MSEK | - | 2022 Q3 |
| 7/15/2022 | 1.58SEK | 1.75SEK | 177.00 MSEK | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Probi stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Probi shareholder structure
| % | Name |
|---|---|
97.43574% | |
0.00000% | |
0.00000% | |
0.00000% |
Probi Beneficial Ownership Filings (SEC 13D/G)
Probi Executives and Management Board
11 members · avg. age 54 · 55 % women
Ms. Anita Johansen (52)
Interim Chief Executive Officer, Vice President - Research & Development
3.99 M SEK
Management
Mr. Per Lindblad (58)
Chief Financial Officer
Mr. Ulf Skold
Interim Chief Financial Officer
Mr. Jim Anthony
Vice President - Operations
Ms. Basudha Bhattarai-Johansson (41)
Vice President - Human Resources and Sustainability
Board of Directors
Ms. Charlotte Hansson (62)
Independent Director
Mr. Joern Andreas (44)
Independent Director · since 2014
Ms. Malin Ruijsenaars (53)
Independent Director
Dr. Jean-Yves Parisot (60)
Non-Executive Chairman of the Board
Ms. Irene Malnoee (66)
Independent Director
Ms. Christina Vegge (51)
Senior Director - Research and Development
Frequently asked questions about Probi
The business model of Probi AB focuses on developing, producing, and selling highly researched and scientifically proven probiotic products. Probi AB specializes in developing strains of live bacteria that promote health and well-being. These strains are then incorporated into a wide range of products, including dietary supplements, functional foods, and medical devices. The company collaborates with leading universities and research institutes to ensure the efficacy and safety of its products. Probi AB's business model emphasizes innovation, quality, and consumer trust, making it a market leader in the probiotics industry.
Probi AB is primarily active in the industries of probiotics, dietary supplements, and functional foods. As a leading provider in the market, Probi AB specializes in developing and manufacturing innovative and science-based probiotic solutions. With a focus on promoting digestive and immune health, the company offers a wide range of products that cater to both consumers and professionals in the healthcare industry. Probi AB's expertise and dedication to quality have established them as a trusted name in the probiotics industry, making them a go-to choice for individuals and businesses seeking reliable and effective probiotic solutions.
The main competitors of Probi AB in the market include companies like Chr. Hansen Holding A/S, DuPont de Nemours, Inc., and Nestlé S.A. These competitors also operate within the probiotics industry and offer similar products and services. However, it is worth noting that Probi AB has established a strong market presence with its innovative probiotic solutions and unique formulations. As a leading player in the market, Probi AB continues to strive for excellence and differentiation, further solidifying its position in the competitive landscape.
Probi AB is a Swedish biotechnology company specializing in probiotics and beneficial bacteria. Founded in 1991, the company has a rich history of innovation in the field of probiotic research. Probi AB has been at the forefront of developing and supplying clinically proven probiotic products to promote gut health and overall well-being. With a strong emphasis on research and development, Probi AB has established itself as a trusted global leader in the probiotics industry. Continually expanding their portfolio, Probi AB has partnered with numerous companies to bring their high-quality probiotic solutions to consumers worldwide.
Probi AB, a leading biotechnology company, has achieved several significant milestones. With their dedication to research and innovation, Probi AB has made notable advancements in the field of probiotics. These include the development of clinically documented strains and the expansion of their product portfolio. Probi AB has also successfully collaborated with renowned partners to enhance their offerings and reach a wider market. Moreover, the company has focused on expanding its global footprint, establishing a strong presence in key regions. Through these achievements, Probi AB continues to solidify its position as a trusted provider of high-quality probiotics for improved health and well-being.
Probi AB, a leading company in the field of probiotics, is primarily present in various countries and regions worldwide. With its headquarters in Lund, Sweden, Probi AB has established a strong global presence. The company's operations span across key markets, including Europe, North America, and Asia. Probi AB's commitment to delivering high-quality probiotic solutions has led to collaborations with numerous partners and the availability of its products in multiple international markets. This global reach enables Probi AB to bring the benefits of probiotics to a diverse range of consumers, enhancing their health and well-being.
Probi AB represents strong values and a solid corporate philosophy. The company focuses on enhancing people's health and well-being through innovative probiotic solutions. Probi AB is dedicated to delivering high-quality products that are supported by extensive research and scientific expertise. With a commitment to transparency and ethical standards, the company aims to create sustainable value for its stakeholders. Probi AB values continuous improvement, collaboration, and a customer-centric approach. By leveraging their expertise in probiotics, Probi AB strives to make a positive impact on people's lives and contribute to a healthier future.
Converted at the current exchange rate, the Probi share trades at 30.84 EUR (348.00 SEK).
The Probi share (PROB.ST) is listed on 5 stock exchanges, including: London (0GZB.L), Stockholm (PROB.ST).
Probi AB is a Swedish company specializing in the development and marketing of probiotics. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB is a pioneer in the field of probiotics and has achieved a leading position in recent years. The company utilizes its expertise in microbiology, clinical research, production, and distribution to bring innovative products to the market. Probi AB's business model focuses on the production and marketing of probiotics, which are live microorganisms that can have a positive effect on health when consumed in sufficient quantities. The company offers a wide range of probiotic products, including those for immune system strengthening, digestion, skin health, and overall health and well-being. Key areas of Probi AB's product range include the development, manufacturing, and marketing of probiotic products for various target groups. This includes dietary supplements, foods and beverages with probiotic ingredients, as well as probiotic bacterial strains for use in medications and cosmetic products. A significant area of Probi AB's product range is the development of probiotic dietary supplements, which contain a high concentration of probiotic bacterial strains that can be specifically used to address certain health issues. These dietary supplements are marketed under various brands and are available in different forms, including capsules, tablets, and powders. Probi AB also offers probiotic foods and beverages that are available in supermarkets and drugstores. These products typically contain a lower concentration of probiotic bacteria and are intended for general use. Examples include yogurts, dairy products, fruit juices, and cereal bars. In addition to probiotic foods and dietary supplements, Probi AB also provides probiotic bacterial strains for medical use. These strains are used in the development of medications that can be used to treat various conditions, including gastrointestinal problems, skin disorders, and infections. In conclusion, Probi AB's business model is based on the development and marketing of probiotics. The company offers a comprehensive range of probiotic products suitable for different target groups. Probi AB is a leading provider of probiotics and utilizes its expertise to bring innovative products to the market and promote awareness of the benefits of probiotics.
The expected revenue of Probi is 703.50 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Probi is 69.08 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Probi is currently 57.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Probi stock.
The price-to-sales ratio (P/S) of Probi is currently 5.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Probi stock.
The Eulerpool Quality Score for Probi is 3/10.
The ISIN of Probi is SE0001280355. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Probi is A0JKFA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Probi is PROB.ST. The ticker symbol is used to trade Probi shares on the stock exchange.
Over the past 12 months, Probi paid a dividend of 1.30 SEK . This corresponds to a dividend yield of about 0.37 %. For the coming 12 months, Probi is expected to pay a dividend of 1.30 SEK.
The current dividend yield of Probi is 0.37 %.
Probi pays a dividend, distributed in the months of May.
Probi paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 1.30 SEK are expected. This corresponds to a dividend yield of 0.37 %.
Probi is assigned to the 'Health' sector.
To receive the latest dividend of Probi from 5/15/2024 amounting to 1.3 SEK, you needed to have the stock in your portfolio before the ex-date on 5/8/2024.
The last dividend was paid out on 5/15/2024.
In the year 2023, Probi distributed 1.3 SEK as dividends.
The dividends of Probi are distributed in SEK.
Probi stock
Probi Peer Group
Probi Ticker
Probi FIGI
All fundamentals and in-depth analysis of Probi
Our stock analysis for Probi stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Probi. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.